Challenges for providing effective hemostasis in surgery and trauma.
D000925:Anticoagulants / Q000627:therapeutic use*; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects / Q000502:physiology; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects / Q000502:physiology; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D005342:Fibrinolysis / Q000187:drug effects / Q000502:physiology; D006470:Hemorrhage / Q000209:etiology* / Q000517:prevention & control*; D006487:Hemostasis / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007431:Intraoperative Complications / Q000188:drug therapy; D011480:Protease Inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000627:therapeutic use; D013927:Thrombosis / Q000188:drug therapy*; D014947:Wounds and Injuries / Q000150:complications*
D000925:Anticoagulants; D000933:Antifibrinolytic Agents; D001779:Blood Coagulation Factors; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa